<p>，/PRNewswire/ -- Ademi 律师事务所正在调查 VYNE（纳斯达克：VYNE）在其最近宣布与 Yarrow Bioscience 的交易中可能存在的信托责任违反和其他法律违规行为。</p>
<p>点击这里了解如何加入我们的调查并获取更多信息，或通过 [email protected] 与我们联系，或拨打免费电话：866-264-3995。您无需支付任何费用或承担任何义务。</p>
<p>在此次交易中，VYNE 股东将获得合并前 VYNE 股东预计将拥有合并后公司约 3% 的股份，而合并前 Yarrow 股东预计将拥有合并后公司约 97% 的股份。VYNE 内部人士将作为控制权变更安排的一部分获得可观的利益。</p>
<p>交易协议不合理地限制了 VYNE 的竞争交易，若 VYNE 接受竞争报价将面临重大罚款。我们正在调查 VYNE 董事会的行为，以及他们是否履行了对所有股东的信托责任。</p>
<p>我们专注于涉及收购、合并和个人股东权利的股东诉讼。如需更多信息，请随时致电我们。律师广告。以往的结果并不保证类似的结果。</p>
<p>联系方式</p>
<p>Ademi &amp; Fruchter LLP</p>
<p>Guri Ademi</p>
<p>免费电话：(866) 264-3995</p>
<p>传真：(414) 482-8001</p>
<p>来源：Ademi LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE4Jk5ld3NJdGVtSWQ9Q0c1MTM2MSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTgxOTM5UFJfTkVXU19VU1BSX19fX19DRzUxMzYx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE4Jk5ld3NJdGVtSWQ9Q0c1MTM2MSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTgxOTM5UFJfTkVXU19VU1BSX19fX19DRzUxMzYx"/></p>

VYNE

<p>Ademi 律师事务所正在调查 VYNE Therapeutics Inc.在与 Yarrow Bioscience 的交易中是否存在潜在的信托责任违反。VYNE 的股东将拥有合并公司约 3% 的股份，而 Yarrow 的股东将拥有 97% 的股份。该交易限制了对 VYNE 的竞争性出价，内部人士获得了可观的利益。调查的重点是 VYNE 董事会是否履行了对股东的信托责任</p>

<p>, /PRNewswire/ -- The Ademi Firm is investigating VYNE (Nasdaq: VYNE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Yarrow Bioscience.</p>
<div class="lb-trans"><p>，/PRNewswire/ -- Ademi 律师事务所正在调查 VYNE（纳斯达克：VYNE）在其最近宣布与 Yarrow Bioscience 的交易中可能存在的信托责任违反和其他法律违规行为。</p>
</div><p>Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.</p>
<div class="lb-trans"><p>点击这里了解如何加入我们的调查并获取更多信息，或通过 [email protected] 与我们联系，或拨打免费电话：866-264-3995。您无需支付任何费用或承担任何义务。</p>
</div><p>In the transaction, VYNE shareholders will receive the pre-Merger VYNE stockholders are expected to own approximately 3% of the combined company, and the pre-Merger Yarrow stockholders are expected to own approximately 97% of the combined company. VYNE insiders will receive substantial benefits as part of change of control arrangements.</p>
<div class="lb-trans"><p>在此次交易中，VYNE 股东将获得合并前 VYNE 股东预计将拥有合并后公司约 3% 的股份，而合并前 Yarrow 股东预计将拥有合并后公司约 97% 的股份。VYNE 内部人士将作为控制权变更安排的一部分获得可观的利益。</p>
</div><p>The transaction agreement unreasonably limits competing transactions for VYNE by imposing a significant penalty if VYNE accepts a competing bid. We are investigating the conduct of the VYNE board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.</p>
<div class="lb-trans"><p>交易协议不合理地限制了 VYNE 的竞争交易，若 VYNE 接受竞争报价将面临重大罚款。我们正在调查 VYNE 董事会的行为，以及他们是否履行了对所有股东的信托责任。</p>
</div><p>We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p>我们专注于涉及收购、合并和个人股东权利的股东诉讼。如需更多信息，请随时致电我们。律师广告。以往的结果并不保证类似的结果。</p>
</div><p>Contacts</p>
<div class="lb-trans"><p>联系方式</p>
</div><p>Ademi &amp; Fruchter LLP</p>
<div class="lb-trans"><p>Ademi &amp; Fruchter LLP</p>
</div><p>Guri Ademi</p>
<div class="lb-trans"><p>Guri Ademi</p>
</div><p>Toll Free: (866) 264-3995</p>
<div class="lb-trans"><p>免费电话：(866) 264-3995</p>
</div><p>Fax: (414) 482-8001</p>
<div class="lb-trans"><p>传真：(414) 482-8001</p>
</div><p>SOURCE Ademi LLP</p>
<div class="lb-trans"><p>来源：Ademi LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE4Jk5ld3NJdGVtSWQ9Q0c1MTM2MSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTgxOTM5UFJfTkVXU19VU1BSX19fX19DRzUxMzYx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CG51361&amp;Transmission_Id=202512181939PR_NEWS_USPR_____CG51361&amp;DateId=20251218"/></p>

19:39 ET
			
			
				Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

股东警示：Ademi 律师事务所正在调查 VYNE Therapeutics Inc.是否为其公众股东争取到了公平的价格